ArticleAnnals of hepato-biliary-pancreatic surgery2026
Efficacy of targeted hepatocellular carcinoma therapy using modified response evaluation criteria in solid tumors and alpha-fetoprotein: A single center retrospective exploratory study.
Article in Annals of hepato-biliary-pancreatic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Backgrounds/Aims: To evaluate the combination of modified response evaluation criteria in solid tumors (mRECIST) with alpha-fetoprotein (AFP) in patients with intermediate-advanced hepatocellular carcinoma receiving combination therapy with a tyrosine kinase inhibitor (TKI) and a programmed cell death protein-1 (PD-1) inhibitor, focusing on stable disease (SD) patients with low AFP levels. Methods: We analyzed 79 patients who received TKI plus PD-1 inhibitor combination therapy from 2018 to 2021. Based on AFP at 8 weeks, patients were divided into Group A (AFP ≥200 ng/mL, n = 26) and Group B (AFP <200 ng/mL, n = 53). Kaplan-Meier and Cox models assessed overall survival (OS) and progression-free survival (PFS). Results: Only Barcelona Clinic Liver Cancer stage C independently predicted OS (hazard ratio [HR] 7.193, Conclusions: This exploratory analysis suggests that the prognostic value of AFP is largely mediated by tumor burden. While mRECIST response predicted PFS but not OS, low-AFP SD patients exhibited favorable outcomes in both PFS and OS. These findings indicate that integrating mRECIST with AFP may enhance response stratification, though prospective validation is necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.